
Ribociclib/Endocrine Therapy Yields Similar pCRs Compared With Chemotherapy in HR+ Early Breast Cancer
Ribociclib (Kisqali) plus endocrine therapy generated low pathologic complete response (pCR) rates that were similar to those seen with standard-of-care (SOC) chemotherapy in patients with intermediate-risk hormone receptor (HR)–positive, HER2-negative …